NEW YORK (GenomeWeb News) – Kindstar Global will validate and implement Advanced Cell Diagnostics' RNAscope technology-based molecular diagnostic assays as part of a partnership the firms announced today.
The firms said that the deal will allow Kindstar to leverage ACD's RNA biomarker analysis platform to offer new cancer diagnostic tests to the 3,300-plus hospitals in Kindstar's network in China.
Initially, the tests being launched include RNAscope HPV, a high-risk HPV test for assessing HPV status in cervical pre-cancer and head and neck cancer, as well as CTCscope for the detection and characterization of circulating tumor cells in blood.
"The new RNAscope-based tests will significantly broaden Kindstar’s oncology test menu offerings," Kindstar Founder and CEO Shiang Huang said in a statement. "The RNAscope platform will also allow Kindstar to more rapidly translate today's advances in cancer research into clinical practice for our physicians and patients."
Financial and other terms of the agreement were not disclosed.
Kindstar provides esoteric diagnostic testing services in China. ACD, based in Hayward, Calif., develops cell and tissue-based research tools.